about
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patientsGlucocorticoids reduce phobic fear in humans.Pharmacotherapy for social phobia.Pharmacotherapy for social anxiety disorder: a systematic review.Social anxiety disorder and alcohol use disorder co-morbidity in the National Epidemiologic Survey on Alcohol and Related Conditions.Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.Pharmacological treatment of social anxiety disorder: a meta-analysis.Brain oxytocin in social fear conditioning and its extinction: involvement of the lateral septumSocial anxiety disorder: radio electric asymmetric conveyor brain stimulation versus sertraline.Clinical features and treatment outcome in Japanese patients with social anxiety disorder: chart review study.Attention training in individuals with generalized social phobia: A randomized controlled trial.The interaction of early life experiences with COMT val158met affects anxiety sensitivity.[Electroencephalography measures in motor skill learning and effects of bromazepam].[Effects of Bromazepam in qEEG by type writing].Levetiracetam in social phobia: a placebo controlled pilot study.Pharmacotherapy for social anxiety disorder (SAnD).Social fear conditioning as an animal model of social anxiety disorder.[Neuromodulatory effects of bromazepam when individuals were exposed to a motor learning task: quantitative electroencephalography (qEEG)].Effect of milnacipran on insight and stress coping strategy in patients with Taijin Kyofusho
P2860
Q24611774-428584DA-811B-47FF-BC14-8A8AF1804583Q30477043-818145B7-CD0D-42EF-98B0-6DAF030345ABQ33208084-C27B2EEC-8B52-49F6-8C1E-94DEBB39B171Q33319625-50296861-38BA-4272-99E0-794CC7218184Q34049058-33962D44-77A3-44BA-B36B-E48906A662D0Q34137084-C71334D5-2C94-43BB-9779-6AE26D9C695AQ34219988-3FF87117-8852-4758-89D1-F5C0823B4CAFQ34499315-12274BD8-1EC8-49AD-AC1E-721049D06713Q35604799-5CE04DDC-2D7A-494A-BDAA-9859B1C79F28Q36554824-3CF8A7F3-C358-45BB-82C7-CE4EE8D3B533Q37486037-8E6D9FF9-75EB-42FC-9AA0-FC0E4CB5F5DDQ44269146-8601A9AB-3D73-42DE-91B4-5BB59775DCC5Q46628505-BA8F5DAE-B1E6-4EFC-A625-FA218CDB402CQ46628512-D75A5486-BF13-486B-872F-F691B44F0BF4Q46705996-9FA1A723-2797-4BE3-A5E4-8C7CF88D2F24Q47593921-7D63CA7A-1B70-4FDE-998E-2B061CD7FF5FQ50749956-5FC294EB-2F6C-48B0-9F6B-17D6603335E4Q52020349-09F14E0B-5F58-4A18-BF70-2A2EC75520A4Q56484420-02261C9C-A2FD-4D02-98D4-B3998E3938FF
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacotherapy of social anxiety disorder.
@ast
Pharmacotherapy of social anxiety disorder.
@en
Pharmacotherapy of social anxiety disorder.
@nl
type
label
Pharmacotherapy of social anxiety disorder.
@ast
Pharmacotherapy of social anxiety disorder.
@en
Pharmacotherapy of social anxiety disorder.
@nl
prefLabel
Pharmacotherapy of social anxiety disorder.
@ast
Pharmacotherapy of social anxiety disorder.
@en
Pharmacotherapy of social anxiety disorder.
@nl
P1476
Pharmacotherapy of social anxiety disorder.
@en
P2093
Michael R Liebowitz
Smita X Antia
P304
P356
10.1016/S0006-3223(01)01294-X
P407
P577
2002-01-01T00:00:00Z